When was Vaderis founded?

Vaderis was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Vaderis located?

Vaderis is headquartered in Basel, Switzerland.

How many employees does Vaderis have?

As of Aug 31, 2026, the latest employee count at Vaderis is 22.

Is Vaderis a funded company?

Vaderis is a funded company, having raised a total of $171M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2020.

When was the latest funding round of Vaderis?

Vaderis' latest funding was a $***** Series B round on Aug 11, 2026, with participation from 8 investors.

Where does Vaderis rank among its competitors?

Vaderis ranks 157th amongst 278 active competitors, of which 78 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Vaderis?

Vaderis' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Vaderis secured the most recent funding round in August, 2026.

Vaderis - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapies for the treatment of rare and orphan diseases. The company is focusing on the treatment of rare and orphan diseases caused by Vascular Malformations. It is developing an oral medicine known as VAD044 to treat the symptoms of Hereditary Haemorrhagic Telangiectasia (HHT) and will reduce the occurrence of new lesions.

Website: vaderis.com
Email ID: *****@vaderis.com

Key Metrics

Founded Year

2017

Location

Basel, Switzerland

Stage

Series B

Total Funding

$171M in 2 rounds

Latest Funding Round

Series B, Aug 11, 2026, $*****

Investors

Medicxi

Ranked

157^th among 278 active competitors

Employee Count

22 as on Aug 31, 2026

Similar Companies

BridgeBio & 312 more

View Vaderis' full profile

Vaderis has raised a total funding of $171M over 2 rounds. Its first funding round was on 2020. Its latest funding round was a Series B round on Aug 11, 2026 for $*****. 8 investors participated in its latest round. Vaderis has 1 institutional investor.

Here is the list of recent funding rounds of Vaderis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 11, 2026	3987154	Series B	5753456	2504812	2969911	4122750
2020	1807	Series A	8988	4941	4901	Medicxi

Access funding benchmarks and valuations. Sign up today!

View details of Vaderis's funding rounds and investors

Vaderis' employee count trend

Vaderis has 22 employees as of Aug 26. Here is Vaderis's employee count trend over the years:

Uncover Vaderis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vaderis include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Vaderis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
157th	Vaderis 2017, Basel (Switzerland), Series B	Developer of therapies for the treatment of rare and orphan diseases	$171M	Medicxi	50/100